Reuters logo
BRIEF-Syros announces FDA acceptance of IND to advance SY-1365
April 10, 2017 / 12:16 PM / 8 months ago

BRIEF-Syros announces FDA acceptance of IND to advance SY-1365

April 10 (Reuters) - Syros Pharmaceuticals Inc

* Syros announces FDA acceptance of IND to advance SY-1365, its first-in-class selective CDK7 inhibitor, into phase 1 clinical trial in patients with advanced solid tumors

* Syros Pharmaceuticals Inc - company on track to initiate study in Q2 of 2017 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below